San Francisco Bay Area biotech stories.
Wednesday, October 5, 2011
Dynavax gets $3M in reworked asthma deal with AstraZeneca
Dynavax Technologies Corp. will receive $3 million upfront after the Berkeley drug developer and pharmaceutical giant AstraZeneca amended a deal to accelerate a trial on an experimental asthma treatment.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)